Abstract
The study of protein-protein interactions (PPIs) has been growing for some years now, mainly as a result of easy access to high-throughput experimental data. Several computational approaches have been presented throughout the years as means to infer PPIs not only within the same species, but also between different species (e.g., host-pathogen interactions). The importance of unveiling the human protein interaction network is undeniable, particularly in the biological, biomedical and pharmacological research areas. Even though protein interaction networks evolve over time and can suffer spontaneous alterations, occasional shifts are often associated with disease conditions. These disorders may be caused by external pathogens, such as bacteria and viruses, or by intrinsic factors, such as auto-immune disorders and neurological impairment. Therefore, having the knowledge of how proteins interact with each other will provide a great opportunity to understand pathogenesis mechanisms, and subsequently support the development of drugs focused on very specific disease pathways and re-targeting already commercialized drugs to new gene products. Computational methods for PPI prediction have been highlighted as an interesting option for interactome mapping. In this paper we review the techniques and strategies used for both experimental identification and computational inference of PPIs. We will then discuss how this knowledge can be used to create protein interaction networks (PINs) and the various methodologies applied to characterize and predict the so-called “disease genes” and “disease networks”. This will be followed by an overview of the strategies employed to predict drug targets.
Keywords: Protein-Protein interaction, Disease networks, Drug targets, Drug design.
Current Topics in Medicinal Chemistry
Title:From Protein-Protein Interactions to Rational Drug Design: Are Computational Methods Up to the Challenge?
Volume: 13 Issue: 5
Author(s): Edgar D. Coelho, Joel P. Arrais and Jose Luis Oliveira
Affiliation:
Keywords: Protein-Protein interaction, Disease networks, Drug targets, Drug design.
Abstract: The study of protein-protein interactions (PPIs) has been growing for some years now, mainly as a result of easy access to high-throughput experimental data. Several computational approaches have been presented throughout the years as means to infer PPIs not only within the same species, but also between different species (e.g., host-pathogen interactions). The importance of unveiling the human protein interaction network is undeniable, particularly in the biological, biomedical and pharmacological research areas. Even though protein interaction networks evolve over time and can suffer spontaneous alterations, occasional shifts are often associated with disease conditions. These disorders may be caused by external pathogens, such as bacteria and viruses, or by intrinsic factors, such as auto-immune disorders and neurological impairment. Therefore, having the knowledge of how proteins interact with each other will provide a great opportunity to understand pathogenesis mechanisms, and subsequently support the development of drugs focused on very specific disease pathways and re-targeting already commercialized drugs to new gene products. Computational methods for PPI prediction have been highlighted as an interesting option for interactome mapping. In this paper we review the techniques and strategies used for both experimental identification and computational inference of PPIs. We will then discuss how this knowledge can be used to create protein interaction networks (PINs) and the various methodologies applied to characterize and predict the so-called “disease genes” and “disease networks”. This will be followed by an overview of the strategies employed to predict drug targets.
Export Options
About this article
Cite this article as:
D. Coelho Edgar, P. Arrais Joel and Luis Oliveira Jose, From Protein-Protein Interactions to Rational Drug Design: Are Computational Methods Up to the Challenge?, Current Topics in Medicinal Chemistry 2013; 13 (5) . https://dx.doi.org/10.2174/1568026611313050005
DOI https://dx.doi.org/10.2174/1568026611313050005 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
“What Is And What Should Never Be”<sup>#</sup>: Use and Misuse of HPV Testing in Cervical Cancer Prevention Strategies
Current Women`s Health Reviews Steroids and the Immune Response in Graves Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nano-pharmaceutical Formulations for Targeted Drug Delivery against HER2 in Breast Cancer
Current Cancer Drug Targets Genomic Organization and Control of the Grb7 Gene Family
Current Genomics Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion
Mini-Reviews in Medicinal Chemistry Subject Index to Volume 4
Current Cancer Drug Targets The Role of HTS in Drug Discovery at the University of Michigan
Combinatorial Chemistry & High Throughput Screening Efficacy and Safety of EGFR Inhibitors in the Treatment of EGFRPositive NSCLC Patients: A Meta-Analysis
Reviews on Recent Clinical Trials Estrogen Receptor-Positive and Estrogen Receptor-Negative Human Breast Cancer Cells: Regulation of Expression of Cancer-Related Genes by Estradiol and Tamoxifen
Current Signal Transduction Therapy The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Curcumin: A Promising Agent Targeting Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry A Review of <i>Aristolochia indica</i>: Ethnomedicinal Uses, Phytochemistry, Pharmacological and Toxicological Effects
Current Traditional Medicine Clinical and <i>In Silico</i> Outcomes of the Expression of miR-130a-5p and miR-615-3p in Tumor Compared with Non-Tumor Adjacent Tissues of Patients with BC
Anti-Cancer Agents in Medicinal Chemistry Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Rational Design of 5-Aminolevulinic Acid Derivatives Aimed at Improving Photodynamic Therapy
Current Medicinal Chemistry - Anti-Cancer Agents S100A8 and S100A9 Overexpression Is Associated with Poor Pathological Parameters in Invasive Ductal Carcinoma of the Breast
Current Cancer Drug Targets Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry S-Phase Kinase-Associated Protein-2 and Nuclear Factor-kappa Beta as Molecular Targets of Oral Burkitt’s Lymphoma Cell Induced by Quinolinone Derivate-Vesnarinone
Current Signal Transduction Therapy Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design